Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

AI is finding its way into every corner of biotech and pharmaceutical research, but like other industries, it's never quite as straightforward to ...

Upstream Bio, Inc. ( (UPB) ) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its ...

Upstream Bio, Inc. ( (UPB)) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors. Upstream Bio, Inc., a clinical-stage biotechnology ...

Upstream Bio, Inc. (NASDAQ:UPB ) is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is ...

“At Upstream Bio (UPB), we continue to make significant progress toward developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Piper Sandler began coverage on shares of Upstream Bio (NASDAQ:UPB – Free Report) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, ...